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ABSTRACT
The MiTF/TFE (MiT) family of basic helix±loop±helix
leucine zipper transcription factors is composed of
four closely related members, MiTF, TFE3, TFEB
and TFEC, which can bind target DNA both as
homo- or heterodimers. Using real-time RT±PCR, we
have analyzed the relative expression levels of the
four members in a broad range of human tissues,
and found that their ratio of expression is tissue-
dependent. We found that, similar to the MiTF gene,
the genes for TFEB and TFEC contain multiple alter-
native ®rst exons with restricted and differential
tissue distributions. Seven alternative 5¢ exons were
identi®ed in the TFEB gene, of which three dis-
played speci®c expression in placenta and brain,
respectively. A novel TFEC transcript (TFEC-C)
encodes an N-terminally truncated TFEC isoform
lacking the acidic activation domain (AAD), and is
exclusively expressed in kidney and small intestine.
Furthermore, we observed that a considerable pro-
portion of the TFEC transcripts splice out protein-
coding exons, resulting in transcription factor
isoforms lacking one or more functional domains,
primarily the basic region and/or the AAD. These
isoforms were always co-expressed with the intact
transcription factors and may act as negative regu-
lators of MiTF/TFE proteins. Our data reveal that
multiple levels of regulation exist for the MiTF/TFE
family of transcription factors, which indicates how
these transcription factors may participate in
various cellular processes in different tissues.
INTRODUCTION
The basic helix±loop±helix leucine zipper (bHLH-LZ) tran-
scription factors MiTF, TFE3, TFEB and TFEC comprise a
family (MiTF/TFE or MiT family) of closely related proteins
that bind DNA as homo- and heterodimers (1). All possible
combinations of DNA-binding MiTF/TFE dimers have been
shown to exist in vitro (1±3).
The members of this family are believed to be implicated in
pivotal developmental and cellular processes in various cell
types. MiTF is involved in the maturation of melanocytes of
neural crest origin, retinal pigment epithelium, and bone
marrow-derived mast cells and osteoclasts (4); whereas TFEB
is essential for placental vascularization (5). TFE3 plays a role
in TGF-b-activated signal transduction (6,7) and B-cell
activation (8), and cooperates with MiTF and TFEC in
osteoclast development (9±11). Furthermore, chromosomal
translocations involving the TFE3 and TFEB genes have been
implicated in subtypes of renal cell carcinomas in children and
young adults. In addition, TFE3 rearrangements were found in
alveolar soft part sarcomas (12±19).
The apparent distinctive cellular functions of MiTF/TFE
family members in the various cell types require regulatory
mechanisms that tightly control MiTF/TFE functioning. Such
mechanisms may involve interactions with cell type-speci®c
factors or speci®c protein modi®cations, but the relative levels
of co-expression of the various transcription factors may be
important as well. Indeed, the expression levels of each of the
four MiTF/TFE family members appear to differ considerably
between cell types (3,20,21), which points towards a model in
which the ratio of MiTF/TFE expression dictates speci®c
dimerization patterns and, subsequently, the expression of
target genes. Although there are indications that heterodimeric
interactions are not essential for proper MiTF/TFE function-
ing (11), MiTF±TFE3 and MiTF±TFEC heterodimers do exist
in vivo, and are believed to be involved in the regulation of cell
type-speci®c genes (10,21,22).
The MiTF gene is expressed in different isoforms that
are under the control of distinct promoters (23,24).
Currently, at least eight major MiTF isoforms have been
identi®ed that are differentially expressed in a variety of
tissues, including melanocytes, heart and mast cells (4,21,24±
28). These isoforms share the important functional domains
of MiTF, including the transactivation domain, basic region,
helix±loop±helix and leucine zipper, but differ in their N-
termini. These N-termini may contribute to the cell type-
speci®c properties of the various isoforms, for example by
recruiting particular cofactors to the transcription apparatus.
Thus far, little is known about the tissue distribution of the
other three MiTF/TFE family members TFE3, TFEB and
TFEC.
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In this study, we have determined the relative expression
levels of MiTF, TFE3, TFEB and TFEC in a broad range of
human tissues, and identi®ed transcript variants. The ratio of
expression of the four MiTF/TFE family members was found
to be unique for each tissue. Furthermore, similar to MiTF, we
found various splice forms of TFEB and TFEC with alterna-
tive ®rst exons and very restricted expression patterns,
suggesting regulation through alternative promoter usage.
MATERIALS AND METHODS
cDNA synthesis and RT±PCR
A panel of total RNA pools from 20 human tissues was
obtained from BD Biosciences Clontech (Palo Alto, CA).
Reverse transcription was performed using 2 mg of total RNA
and Superscript II (Life Technologies, Grand Island, NY)
according to the manufacturer's instructions. RT reactions
were performed using random hexamers, except for the
experiment dealing with alternative intron 7 splicing of TFEC
transcripts, for which oligo-dT priming was used in order to
minimize contamination with incompletely spliced nuclear
mRNAs. Primers used for PCR were TFEB-1Af (5¢-CAAC-
AAGGGAAGGTGACATGAAAGG-3¢), TFEB-1Bf (5¢-CG-
GACAGATTGACCTTCAGAGG-3¢), TFEB-1C1for (5¢-AT-
GCCTGAGAGGGGGTCGGAG-3¢), TFEB-1C2for (5¢-GA-
GAGGAGGGAGATGAAAACACACC-3¢), TFEB-1Df (5¢-
TTAGAGCTCGCTGGGGAAGTGCAG-3¢), TFEB-1Ef (5¢-
TTGAGGTCCCTGCCTGCTAACCTGACG-3¢), TFEB-1Ff
(5¢-CCTCCTTCCAGGGGGCTGCC-3¢), TFEB-1Gf (5¢-GG-
TGTGAGCTGACGAGAGCTTCAG-3¢), TFEBexon2r (5¢-
AACCCTATGCGTGACGCCATGGTGG-3¢), TFEC-1Af
(5¢-ACTTGTCCCAGCAAGACCACA-3¢), TFEC-1Bf (5¢-
AAATCCACTCATTGCTGGTCC-3¢), TFEC-1Cf (5¢-GAG-
AAAACCATTGCTATTGTGAAGG-3¢), TFECr (5¢-TTGT-
AGCCACTTGATGTACTCCACT-3¢), TFEC-6f (5¢-CACT-
CTTATTCCAAAGTCTAATGATCCT-3¢), TFECintron7r
(5¢-CCTTGAGGCAATGAAATCCATAGC-3¢) and TFEC-
8r (5¢-TCTTTGTTCCTCTTTCAATGCAGC-3¢).
Real-time quantitative RT±PCR
Real-time RT±PCR on MiTF/TFE cDNAs was performed on a
TaqMan ABI 7700 Sequence Detection System (PE Applied
Biosystems) using heat-activated TaqDNA polymerase
(Amplitaq Gold; PE Applied Biosystems) as previously
described (18). The speci®city of the primer/probe sets for
each of the four MiTF/TFE members relative to the other three
was con®rmed using different dilutions of DNA constructs
containing the bHLH-LZ-encoding regions of TFE3, TFEB,
TFEC or MiTF. The four primer/probe sets recognized their
speci®c MiTF/TFE templates with almost identical ef®cien-
cies. For quantitative analysis of the data, TFEB CT-values
were normalized to those of endogenous GAPDH (with use of
standard TaqMan human GAPDH control reagents; PE
Applied Biosystems) using the DDCT technique (29).
Rapid ampli®cation of 5¢-cDNA ends (5¢-RACE)
The 5¢-RACE System (Invitrogen) was used according to the
manufacturer's instructions. A TFEB gene-speci®c primer (5¢-
ATTTCAGGATTGATGTAGC-3¢) was used for TFEB cDNA
synthesis. The TFEB-speci®c primers (located in exon 2) were
TFEB 5¢R442 (5¢-TATTGATGGCCGGGGTGGGCG-3¢) and
TFEB 5¢R376 (5¢-TAATGCATGACAGCCTGTTGCT-
GCATG-3¢), of which the latter was used for the hemi-nested
reaction. For the TFEC 5¢-RACE we used the TFEC gene-
speci®c primer (5¢-TTTCAATGAGGTTGTGG-3¢) for cDNA
synthesis and primers TFEC 5¢R547 (5¢-ATTGGTA-
GACTACTTGGACAAGAAGCAC-3¢) and TFEC 5¢R494
(5¢-AATTCCTTGTTCACCGCTATACACATCC-3¢) for the
PCR. The PCR pro®le was composed of ®ve cycles of 30 s at
94°C, 1 min at 48°C, 30 s at 72°C; ®ve cycles of 30 s at 94°C,
1 min at 52°C, 30 s at 72°C; 25 cycles of 30 s at 94°C, 1 min at
55°C, 30 s at 72°C. PCR products were separated on agarose
gels, puri®ed, subcloned into the pGemT vector (Promega,
Leiden, The Netherlands), and subsequently sequenced using
a Ready Reaction Dye Terminator Cycle sequencing kit (PE
Applied Biosystems, Foster City, CA) and an ABI 3700
automated sequencer (PE Applied Biosystems).
Transfection experiments and western blotting
Full-length RT±PCR products corresponding to the wild-type
TFEB and TFEC transcripts were cloned into the eukaryotic
expression vector pSG8-VSV (30). The TFEC cDNAs were
cloned in-frame in front of a VSV-tag. Transfection and
western blotting was performed as previously described (18).
For immunodetection of TFEB, an af®nity-puri®ed rabbit
polyclonal anti-TFEB-N antiserum was used (18). The VSV-
tagged TFEC was detected using the mouse anti-VSV
monoclonal antibody P5D4. Immunostaining was performed
using chemiluminesence.
RESULTS
The MiTF/TFE transcription factor family shows a
speci®c tissue distribution
In vitro, TFE3, TFEB, TFEC and MiTF form homo- and
heterodimers in all possible combinations to bind DNA (1).
Based on this observation, it can be hypothesized that
differential tissue-speci®c dimerization may determine the
repertoire of target genes that are expressed. In order to
analyze the relative expression levels of the MiTF/TFE
members in different tissues, we performed quantitative
real-time RT±PCR analysis on a panel of 20 human tissues.
We established primer sets located within the bHLH-encoding
regions, capable of detecting all MiTF/TFE isoforms. As
shown in Figure 1A, the expression ratios of the four MiTF/
TFE members showed large variations between tissues and
none of the members appeared to be co-regulated. In
Figure 1B, the same set of data is represented as absolute
levels, which allows comparison of the MiTF/TFE expression
levels between tissues. Although each of the four members
could be detected in all tissues examined, TFEC and MiTF
showed more variation in expression between tissues (Fig. 1B).
Highest expression levels of both TFE3 and TFEB were found
in placenta and lung, but their expression levels differed in
adrenal gland (relatively high for TFE3), and prostate and
spleen (higher levels of TFEB). MiTF was most prominent in
the uterus. The TFEC gene was expressed at lower levels
compared to the other three members, and was prominent in
spleen, kidney, bone marrow and small intestine. These data
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indicate that expression of each of the four members must be
regulated in a tissue-speci®c manner.
The TFEB gene contains alternative 5¢-non-coding exons
The temporal and spatial expression of the human MiTF gene
is controlled by the differential usage of at least six distinct
promoters, driving the expression of transcripts with alterna-
tive ®rst exons (24±26,28). We investigated whether a similar
mechanism might act in the other MiTF/TFE members. The
TFEB gene, which resides on chromosome 6p21, is composed
of nine exons, with a postulated initiation ATG preceded by a
perfect ribosomal binding (`Kozak') sequence in exon 2 (18).
The numerous TFEB-encoding ESTs that are present in the
nucleotide sequence databases reveal the presence of at least
three frequently occurring alternative 5¢ exons (GenBank
Accession nos M33782, NM007162 and AK095061, respect-
ively). To validate whether more TFEB transcripts might exist
that differ in their 5¢-end, we performed 5¢-RACE analysis on
cDNA pools of various tissues, using TFEB-speci®c primers
located in exon 2. Using this approach, we were able to
identify TFEB transcripts containing seven distinct alternative
5¢ exons, of which ®ve were novel, named exons 1a to 1g1
(Table 1 and Fig. 2). The resulting TFEB transcripts were
designated TFEB-A to TFEB-G, respectively. The TFEB-B
(31) and TFEB-C transcripts were found in liver, kidney,
spleen and brain, whereas the remaining ®ve TFEB transcripts
were found in only one of the tissues examined (Table 1). In
addition, we observed three alternative splicing events in the
5¢ region of the TFEB-G transcripts, generating transcripts
containing either 1g1 alone, 1g1/1g2 or the complete exon 1g
at their 5¢-ends (Fig. 2B and Table 1). Similarly, we found
alternative TFEB-E splice variants in the brain cDNA pool
which contained exon 1c2 and, in some cases, the entire
sequence from 1e to 1c2 (Fig. 2B). This latter longest TFEB-E
variant corresponds to the previously identi®ed full-length
TFEB transcript AK095061. Another 5¢-RACE product,
obtained from skeletal muscle cDNA, appeared to be an
alternatively spliced variant of TFEC-C, lacking exon 1c2
(Fig. 2B). Of all alternative 5¢ exons, only exon 1a contains a
putative in-frame ATG codon which, if active, would result in
14 extra N-terminal amino acids in TFEB-A. Therefore, most
alternative 5¢ exons are non-coding. Together, we conclude
from these data that the TFEB gene contains multiple
alternative ®rst exons.
Differential tissue distribution of alternative TFEB
transcripts
To analyze the relative expression of the above TFEB variants
in human tissues, we performed RT±PCR analysis on the
human tissue panel using alternative exon 1-speci®c primers
for the various transcripts. Six TFEB transcripts showed
restricted and clearly different tissue distribution patterns
(Fig. 2C). Only TFEB-D could not be ampli®ed in any of the
tissues, possibly due to very low expression levels. Despite the
fact that the splice acceptor site of exon 1d perfectly matches
the consensus criteria (Table 1), the TFEB-D transcript was
found only once in our 5¢-RACE analysis, and its existence
thus still needs to be con®rmed. TFEB-B and TFEB-C showed
the broadest tissue distribution, with TFEB-C being detectable
in all tissues but liver. Interestingly, TFEB-A was almost
exclusively expressed in placenta, with only minor levels of
expression in kidney, lung and prostate. Similarly, the TFEB-
E and TFEB-G transcripts appeared to be brain-speci®c,
whereas TFEB-F was highest in spleen (Fig. 2C).
The multiple RT±PCR products observed in the TFEB-E
and TFEB-G panels were isolated and sequenced, and
appeared to correspond to the splice variants identi®ed with
5¢-RACE analysis (Fig. 2B). Based on the intensities of these
products in the two panels, these splice variants appear to be
expressed in a tissue-speci®c manner. Despite their differen-
Figure 1. Bar graphs showing the relative expression levels of the MiTF/
TFE transcription factors in twenty human tissues, as analyzed by real-time
RT±PCR. (A) The sum of the expression levels of TFE3, TFEB, TFEC and
MiTF is set to 100% to enable comparison of the MiTF/TFE expression
ratios in each tissue. (B) The same data set depicted as absolute levels to
illustrate the variation in MiTF/TFE expression between tissues. The data
were based on two independent in duplo experiments.
Table 1. Alternative 5¢ exons of the TFEB gene and their occurrence in
different tissues
5¢ exon Sequence at junction Number of 5¢-RACE products/total
Exon Intron Liver
n = 5
Kidney
n = 11
Brain
n = 54
Spleen
n = 31
1a gctcaggctg gtgagtgggg 8
1b tcagagcgag gtgagcggga 4 2 15 14
1c2 ctggtacatg gtgagtacat 1 1 24 11
1d ggaagtgcag gttaattact 1
1e taacctgacg gtatgctttc 5
1f cctctcgaag gtatgagagc 6
1g1 agagcttcag gtgggagcct 3
1g2 ggtgaaagag gtcagtggat 6
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tial tissue distribution, none of these variants contain upstream
ATG start codons, indicating that they all encode TFEB
proteins with identical N-termini. Variations in the 5¢-UTR
sequences might, however, in¯uence the ef®ciency of trans-
lation, as has been described for the cyclin-dependent kinase
inhibitor p18INK4c and the nitric oxide synthase gene NOS1
(32,33). We conclude that alternative transcripts may control
the expression of TFEB in a tissue-speci®c manner.
Differential tissue distribution of TFEC variants
In the TFEC gene (Fig. 3), at least two alternative transcription
start sites appear to be present, resulting in transcripts here
referred to as TFEC-A and TFEC-B (GenBank Accession nos
BM807021 and NM012252, respectively). Exon 2 is shared by
the two TFEC variants, and contains the ATG start codon. The
TFEC-A variant has not been described before, and contains
three exons preceding exon 2. Two additional in-frame ATG
codons are present in exon 1a3 (Fig. 3A). Using 5¢-RACE
analysis on human kidney cDNA, we identi®ed a third TFEC
transcript, which initiates in an alternative 5¢ exon positioned
between exons 3 and 4 (exon 1c; Fig. 3A). RT±PCR analysis
using a reverse primer in exon 1c in combination with a
forward primer in any of the upstream exons never resulted in
a PCR product, indicating that exon 1c is indeed the ®rst exon
of this transcript. TFEC-C thus lacks the protein-coding exons
2 and 3. In-frame ATG start codons were present in both exon
Figure 2. (A) The genomic organization of the human TFEB gene. The ATG start codon in exon 2 and TAG stop codon in exon 9 are indicated. Dotted lines
depict alternative splicing. A 1600-bp CpG island colocalizes with exons 1b, 1c1 and part of exon 1d. (B) Alternative splice events in the 5¢-regions of
TFEB-C, TFEB-E and TFEB-G. Dotted lines depict alternative splicing. The largest of three TFEB-G derived products contained the complete exon 1g,
including 1g1, 1g2 and the intermediate `intronic' sequence. Accession numbers of the nine novel TFEB transcript fragments are AJ608786±AJ608794.
(C) Tissue distribution of the human TFEB variants determined by RT±PCR analysis on 20 human tissues.
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1c and exon 4. Subcloning of the TFEC-C cDNA in front of an
in-frame VSV-tag, and subsequent transfection into COS-1
cells, revealed that the transcript indeed encodes a protein of
the predicted size (~33 kDa; Fig. 3B). A TFEC-C transcript
was also found in the mouse (Genbank Accession no.
BB843583), and appeared to be highly conserved at both the
nucleotide (83%) and amino acid (86%) level.
Similar to TFEB, the tissue distributions of TFEC tran-
scripts was analyzed by RT±PCR (Fig. 3C). TFEC-A was
predominantly expressed in testis, thymus, trachea, colon and
prostate. TFEC-B showed a broader tissue distribution, and
appeared to be absent only from heart and liver, whereas the
newly identi®ed TFEC-C transcript was exclusively expressed
in kidney and small intestine.
Together, these ®ndings suggest that next to the MiTF gene,
the TFEB and TFEC genes also express transcripts with
alternative 5¢ exons that show restricted and clearly distinct
tissue distributions.
Unlike MiTF, TFEB and TFEC, there are no TFE3
transcripts known that would indicate the presence of
alternative ®rst exons. Furthermore, RT±PCR analysis on
the human tissue panel, using a primer set that included the
®rst exon and a primer set located within the bHLH domain,
gave identical tissue distributions (data not shown). Therefore,
we assume that expression of the TFE3 gene is regulated by a
single promoter.
Alternative splicing of exons encoding functional
domains
RT±PCRs with 5¢ exon-speci®c primers generated multiple
bands in all cases (Fig. 3C), which indicates that from each
transcription start site various alternative transcripts can be
generated. To reveal their identity, we have isolated and
sequenced these different products. The largest RT±PCR
product in the TFEC-A panel represents a transcript containing
all protein-coding exons, whereas the lower band was found to
lack the N-terminal acidic activation domain (AAD)-encoding
exon 3 and the basic region-encoding exon 5 (D3/D5). In testis,
the tissue that showed the highest expression of TFEC-A,
two minor additional products could be isolated as well, and
turned out to represent TFEC transcripts lacking exons 2 and 3
(D2/D3) and exons 2, 3 and 5 (D2/D3/D5), respectively.
Interestingly, the relative expression ratios of these TFEC-A
variants was different between the various tissues. Similarly,
the doublet in the TFEC-B panel (Fig. 3C) appeared to
represent transcripts that differ in the presence or absence of
exon 3, and were previously presented as TFEC-L (long) and
TFEC-S (short), respectively (34). Apparently, these two
Figure 3. (A) Schematic representation of the human TFEC gene containing three alternative 5¢ exons. For clarity reasons, exon sizes are depicted ®ve times
larger than the intron sizes. Relevant start and stop codons are indicated, as well as the regions encoding the AAD, the basic region, the bHLH-LZ and the
proline-rich activation domain and serine-rich stretch (Pro-AD/Ser). Dotted lines depict alternative splicing. The accession number of the novel TFEC-C
transcript fragment is AJ608795. (B) Western blot analysis of COS-1 cells transfected with empty vector (lane 1) or VSV-tagged TFEC-C cDNA (lane 2).
(C) Tissue distribution of the TFEC transcripts determined by RT±PCR analysis. For each of the panels, the various PCR fragments were isolated and
sequenced. Next to the full-length TFEC variants, alternatively spliced transcripts were ampli®ed that lacked exon 2 (D2), exon 3 (D3) and/or exon 5 (D5).
The lower two panels show RT±PCR products using a forward primer in exon 6, and reverse primers in either exon 8 or intron 7, which depict the presence
of TFEC transcripts encoding the complete C-terminus of TFEC or a truncated C-terminus, respectively. In order to enrich for active cytoplasmic transcripts,
we used oligo-dT priming in the reverse transcription reaction.
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forms are mostly co-expressed, although the ratio in each of
the tissues examined was different. Finally, we also detected a
weakly expressed, smaller variant of TFEC-C, which differed
from the major form in that it again lacked the basic region-
encoding exon 5 (D5).
Apart from exon 3 and exon 5, we found indications for
another frequently occurring alternative splicing event in the
TFEC gene. This alternative splicing event involves the C-
terminus of TFEC, which became apparent when we used a
reverse RT±PCR primer positioned in exon 8, the 3¢-terminal
exon of the gene. The C-terminal region of the protein is
highly conserved within the MiTF/TFE family and contains
two functional domains, namely a proline-rich activation
domain (35), and a serine-rich region that contains an Rsk-1
phosphorylation site that is known to play a role in
transactivation and degradation of MiTF (36). In most, if not
all, TFEC expressing tissues, transcripts could be detected in
which intron 7 is still present. Translation of such a transcript
would result in a truncated TFEC protein that lacks the
proline-rich activation domain and the serine-rich domain
(Fig. 3C, two bottom panels). Although the RT±PCRs were
performed under semi-quantitative conditions, it appears that
the presence or absence of intron 7 in the TFEC transcripts
again varies between tissues.
The expression of alternatively spliced variants of TFEB
was less apparent than that of TFEC. The TFEB variants were
mainly expressed as full-length transcripts that contained an
alternative exon 1 followed by the protein-encoding exons 2 to
9. Nevertheless, we did ®nd alternatively spliced TFEB
transcripts in a limited set of tissues lacking exon 3 and exon 4,
of which the latter encodes the AAD (data not shown).
In conclusion, we have established MiTF/TFE expression
levels and ratios in 20 human tissues. These expression
patterns appeared to be unique for each tissue. Furthermore,
we identi®ed (novel) alternative 5¢ exons in the proximal
regions of the TFEB and TFEC genes, and demonstrated that
the expression of MiTF/TFE isoforms lacking functional
domains is a characteristic for all members of the family, but is
predominant for TFEC.
DISCUSSION
We have determined the expression pro®le of the MiTF/TFE
family of bHLH-LZ transcription factors in a large series of
human tissues and identi®ed alternative transcripts generated
by the respective genes. We found that the ratio in which these
four members are expressed differs extensively between the
various tissues examined. The tight spatial regulation of
MiTF/TFE expression appears to be mediated at least in part
by alternative transcription start sites. Next to MiTF (4,21,24±
28), both TFEB and TFEC were found to express a variety of
transcripts that contain alternative 5¢ (non-coding) exons and
show very restricted differential tissue distributions. The use
of alternative 5¢ exons in a tissue-speci®c manner point
towards the existence of alternative promoters in both genes.
Indeed, through the characterization of an oligo-capped
human cDNA library, the exact position of the transcription
start site and thereby the position of a core-promoter region
has been identi®ed for the TFEB-E transcript (see http://
dbtss.hgc.jp/). Furthermore, three more downstream located
exons (1b, 1c1 and 1d) are positioned within a 1600-bp CpG
island that is conserved between human and mouse. Such
regions are known to colocalize with 60% of the human
promoters (37). Although we cannot exclude that some of the
TFEB variants we found are the result of alternative
transcription start site usage within a single promoter region
or alternative splicing in the 5¢-UTR, our data strongly
suggests the presence of alternative promoters in the TFEB
and TFEC genes.
We identi®ed seven alternative 5¢ exons in the TFEB gene.
Except for TFEB-A, all these 5¢ exons appeared to be non-
coding, suggesting that the respective transcripts encode the
same TFEB protein. Together, the TFEB transcripts drive the
ubiquitous expression of TFEB. However, each transcript was
represented in a restricted set of tissues, and we found three
novel TFEB transcripts that were predominantly expressed in
one particular tissue. Of these three TFEB transcripts, TFEB-E
and TFEB-G appeared to be speci®cally abundant in brain,
whereas TFEB-A was expressed almost exclusively in pla-
centa. Previous studies in transgenic mice already revealed
that TFEB, but not the other MiTF/TFE members, plays an
essential role in placental vascularization during the early
stages of placental development (5,11). Our ®nding of a
placenta-enriched TFEB variant points towards a similar role
in the human placenta. This placental expression of TFEB
appears to be controlled by a distinct promoter. A total of three
alternative 5¢ exons were found to be present in the TFEC
gene, of which two (exons 1a and 1c) were novel. The three
TFEC transcripts were all expressed in a limited set of tissues,
with TFEC-C being exclusively found in kidney and small
intestine. Despite this restricted expression of TFEC variants,
TFEC was observed in all tissues examined, similar to TFEB.
From these data, we conclude that next to the MiTF gene, the
genes for TFEB and TFEC are also equipped with different
alternative ®rst exons and multiple promoter regions. Such a
genomic organization allows a tightly regulated expression of
the respective transcription factors in a cell type-speci®c
manner, and may explain the observed tissue-speci®c ratios of
the four MiTF/TFE members. These relative expression levels
may affect MiTF/TFE homo- or heterodimerization and,
thereby, in¯uence the regulation of downstream target genes
(18).
Another important mechanism for functional regulation
may be the co-expression of MiTF/TFE members with
isoforms lacking particular functional domains. Co-expression
of such isoforms appears to occur for all MiTF/TFE proteins,
but was most evident for TFEC. Multiple splice variants,
lacking exons encoding a conserved mitogen-activated protein
kinase (MAPK) phosphorylation site (exon 2), the N-terminal
AAD (exon 3), the basic region (exon 5), and/or the C-
terminal proline-rich activation domain and serine-rich stretch
(exon 8), were co-expressed with TFEC-A, TFEC-B and
TFEC-C. These domains are highly conserved in the MiTF/
TFE family members and all play a role in the transactivating
capacities of the proteins. Therefore, these isoforms may act as
weaker transactivators or even repressors, as has been shown
for TFE3 (35,38) and MiTF (23,36,39). Furthermore, splice
variants lacking the basic region have been described for
MiTF as well (23), and may act as negative regulators by
forming non-DNA-binding homo- or heterodimers similar to
what has been proposed for the HLH Id proteins (40,41). The
N-terminally truncated TFEC-C isoform appears to be
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expressed from an internal promoter, and also lacks the
MAPK phosphorylation site and the AAD. Remarkably, this
isoform was exclusively expressed in kidney and small
intestine, which might indicate that it is involved in the
regulation of processes that are shared by these two tissues,
like for example (re)absorption of ions and/or organic
compounds. The co-expression of these different TFEC
isoforms may allow ®ne regulation of MiTF/TFE activities,
and may be crucial for the proper spatio-temporal functioning
of these transcription factors. Other well-characterized
examples of genes that produce multiple isoforms with a
regulatory role are p63 and p73, two members of the p53 gene
family. Both genes produce splice variants as well as
N-terminally truncated forms that originate from internal
promoters (42,43). These isoforms act as dominant-negative
regulators of p63, p73 and their close relative p53 by forming
heteromeric complexes (43±45). The truncated isoforms were
found to be vital for normal growth and development, and
provide a regulatory system for modulating cell survival and
cell death (42,46). Based on our ®ndings, we hypothesize that
the various MiTF/TFE isoforms lacking functional domains
may form heterodimers with the full-length counterparts and,
thereby, modulate their role in downstream target gene
regulation, either by preventing DNA binding, changing the
DNA-binding speci®city, or altering the binding capacities of
transcriptional cofactors. In particular, the TFEC gene, which
generates the widest variety of functionally distinct isoforms,
may play a prominent role in such regulatory mechanisms.
ACKNOWLEDGEMENTS
The authors thank L. van der Logt, A. C. Poirters and E. M.
Evers for technical assistance and advice. This work was
supported by a grant from the Dutch Cancer Society (Koningin
Wilhelmina Fonds), KUN 99±1912.
REFERENCES
1. Hemesath,T.J., Steingrimsson,E., McGill,G., Hansen,M.J., Vaught,J.,
Hodgkinson,C.A., Arnheiter,H., Copeland,N.G., Jenkins,N.A. and
Fisher,D.E. (1994) Microphthalmia, a critical factor in melanocyte
development, de®nes a discrete transcription factor family. Genes Dev.,
8, 2770±2780.
2. Fisher,D.E., Carr,C.S., Parent,L.A. and Sharp,P.A. (1991) TFEB has
DNA-binding and oligomerization properties of a unique helix±loop±
helix/leucine-zipper family. Genes Dev., 5, 2342±2352.
3. Zhao,G.Q., Zhao,Q., Zhou,X., Mattei,M.G. and de Crombrugghe,B.
(1993) TFEC, a basic helix±loop±helix protein, forms heterodimers with
TFE3 and inhibits TFE3-dependent transcription activation. Mol. Cell.
Biol., 13, 4505±4512.
4. Hodgkinson,C.A., Moore,K.J., Nakayama,A., Steingrimsson,E.,
Copeland,N.G., Jenkins,N.A. and Arnheiter,H. (1993) Mutations at the
mouse microphthalmia locus are associated with defects in a gene
encoding a novel basic-helix±loop±helix-zipper protein. Cell, 74,
395±404.
5. Steingrimsson,E., Tessarollo,L., Reid,S.W., Jenkins,N.A. and
Copeland,N.G. (1998) The bHLH-Zip transcription factor Tfeb is
essential for placental vascularization. Development, 125, 4607±4616.
6. Hua,X., Liu,X., Ansari,D.O. and Lodish,H.F. (1998) Synergistic
cooperation of TFE3 and smad proteins in TGF-b-induced transcription
of the plasminogen activator inhibitor-1 gene. Genes Dev., 12,
3084±3095.
7. Hua,X., Miller,Z.A., Benchabane,H., Wrana,J.L. and Lodish,H.F. (2000)
Synergism between transcription factors TFE3 and Smad3 in
transforming growth factor-beta-induced transcription of the Smad7
gene. J. Biol. Chem., 275, 33205±33208.
8. Merrell,K., Wells,S., Henderson,A., Gorman,J., Alt,F., Stall,A. and
Calame,K. (1997) The absence of the transcription activator TFE3
impairs activation of B cells in vivo. Mol. Cell. Biol., 17, 3335±3344.
9. Weilbaecher,K.N., Motyckova,G., Huber,W.E., Takemoto,C.M.,
Hemesath,T.J., Xu,Y., Hershey,C.L., Dowland,N.R., Wells,A.G. and
Fisher,D.E. (2001) Linkage of M-CSF signaling to Mitf, TFE3, and the
osteoclast defect in Mitf(mi/mi) mice. Mol. Cell, 8, 749±758.
10. Mansky,K.C., Sulzbacher,S., Purdom,G., Nelsen,L., Hume,D.A.,
Rehli,M. and Ostrowski,M.C. (2002) The microphthalmia transcription
factor and the related helix±loop±helix zipper factors TFE-3 and TFE-C
collaborate to activate the tartrate-resistant acid phosphatase promoter.
J. Leukoc. Biol., 71, 304±310.
11. Steingrimsson,E., Tessarollo,L., Pathak,B., Hou,L., Arnheiter,H.,
Copeland,N.G. and Jenkins,N.A. (2002) Mitf and Tfe3, two members of
the Mitf-Tfe family of bHLH-Zip transcription factors, have important
but functionally redundant roles in osteoclast development. Proc. Natl
Acad. Sci. USA, 99, 4477±4482.
12. Weterman,M.A., Wilbrink,M. and Geurts van Kessel,A. (1996) Fusion of
the transcription factor TFE3 gene to a novel gene, PRCC, in
t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc. Natl
Acad. Sci. USA, 93, 15294±15298.
13. Weterman,M.A., Wilbrink,M., Janssen,I., Janssen,H.A., van den Berg,E.,
Fisher,S.E., Craig,I. and Geurts van Kessel,A. (1996) Molecular cloning
of the papillary renal cell carcinoma-associated translocation
(X;1)(p11;q21) breakpoint. Cytogenet. Cell. Genet., 75, 2±6.
14. Clark,J., Lu,Y.J., Sidhar,S.K., Parker,C., Gill,S., Smedley,D.,
Hamoudi,R., Linehan,W.M., Shipley,J. and Cooper,C.S. (1997) Fusion of
splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in
papillary renal cell carcinoma. Oncogene, 15, 2233±2239.
15. Heimann,P., El Housni,H., Ogur,G., Weterman,M.A., Petty,E.M. and
Vassart,G. (2001) Fusion of a novel gene, RCC17, to the TFE3 gene in
t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas. Cancer
Res., 61, 4130±4135.
16. Ladanyi,M., Lui,M.Y., Antonescu,C.R., Krause-Boehm,A., Meindl,A.,
Argani,P., Healey,J.H., Ueda,T., Yoshikawa,H., Meloni-Ehrig,A. et al.
(2001) The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma
fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
Oncogene, 20, 48±57.
17. Argani,P., Antonescu,C.R., Illei,P.B., Lui,M.Y., Timmons,C.F.,
Newbury,R., Reuter,V.E., Garvin,A.J., Perez-Atayde,A.R., Fletcher,J.A.
et al. (2001) Primary renal neoplasms with the ASPL-TFE3 gene fusion
of alveolar soft part sarcoma: a distinctive tumor entity previously
included among renal cell carcinomas of children and adolescents.
Am. J. Pathol., 159, 179±192.
18. Kuiper,R.P., Schepens,M., Thijssen,J., van Asseldonk,M.,
van den Berg,E., Bridge,J., Schuuring,E., Schoenmakers,H.F.P.M. and
Geurts van Kessel,A. (2003) Upregulation of the transcription factor
TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter
substitution. Hum. Mol. Genet., 12, 1661±1669.
19. Davis,I.J., Hsi,B.L., Arroyo,J.D., Vargas,S.O., Yeh,Y.A., Motyckova,G.,
Valencia,P., Perez-Atayde,A.R., Argani,P., Ladanyi,M. et al. (2003)
Cloning of an alpha-TFEB fusion in renal tumors harboring the
t(6;11)(p21;q13) chromosome translocation. Proc. Natl Acad. Sci. USA,
100, 6051±6056.
20. Rehli,M., Lichanska,A., Cassady,A.I., Ostrowski,M.C. and Hume,D.A.
(1999) TFEC is a macrophage-restricted member of the microphthalmia-
TFE subfamily of basic helix±loop±helix leucine zipper transcription
factors. J. Immunol., 162, 1559±1565.
21. Takemoto,C.M., Yoon,Y.J. and Fisher,D.E. (2002) The identi®cation and
functional characterization of a novel mast cell isoform of the
microphthalmia-associated transcription factor. J. Biol. Chem., 277,
30244±30252.
22. Weilbaecher,K.N., Hershey,C.L., Takemoto,C.M., Horstmann,M.A.,
Hemesath,T.J., Tashjian,A.H. and Fisher,D.E. (1998) Age-resolving
osteopetrosis: a rat model implicating microphthalmia and the related
transcription factor TFE3. J. Exp. Med., 187, 775±785.
23. Hallsson,J.H., Favor,J., Hodgkinson,C., Glaser,T., Lamoreux,M.L.,
Magnusdottir,R., Gunnarsson,G.J., Sweet,H.O., Copeland,N.G.,
Jenkins,N.A. et al. (2000) Genomic, transcriptional and mutational
analysis of the mouse microphthalmia locus. Genetics, 155, 291±300.
24. Udono,T., Yasumoto,K., Takeda,K., Amae,S., Watanabe,K., Saito,H.,
Fuse,N., Tachibana,M., Takahashi,K., Tamai,M. et al. (2000) Structural
organization of the human microphthalmia-associated transcription factor
Nucleic Acids Research, 2004, Vol. 32, No. 8 2321
 at K
atholieke U
niversiteit on July 13, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
gene containing four alternative promoters. Biochim. Biophys. Acta,
1491, 205±219.
25. Amae,S., Fuse,N., Yasumoto,K., Sato,S., Yajima,I., Yamamoto,H.,
Udono,T., Durlu,Y.K., Tamai,M., Takahashi,K. et al. (1998)
Identi®cation of a novel isoform of microphthalmia-associated
transcription factor that is enriched in retinal pigment epithelium.
Biochem. Biophys. Res. Commun., 247, 710±715.
26. Fuse,N., Yasumoto,K., Takeda,K., Amae,S., Yoshizawa,M., Udono,T.,
Takahashi,K., Tamai,M., Tomita,Y., Tachibana,M. et al. (1999)
Molecular cloning of cDNA encoding a novel microphthalmia-associated
transcription factor isoform with a distinct amino-terminus. J. Biochem.,
126, 1043±1051.
27. Oboki,K., Morii,E., Kataoka,T.R., Jippo,T. and Kitamura,Y. (2002)
Isoforms of mi transcription factor preferentially expressed in cultured
mast cells of mice. Biochem. Biophys. Res. Commun., 290, 1250±1254.
28. Takeda,K., Yasumoto,K., Kawaguchi,N., Udono,T., Watanabe,K.,
Saito,H., Takahashi,K., Noda,M. and Shibahara,S. (2002) Mitf-D, a
newly identi®ed isoform, expressed in the retinal pigment epithelium and
monocyte-lineage cells affected by Mitf mutations. Biochim. Biophys.
Acta, 1574, 15±23.
29. Fink,L., Seeger,W., Ermert,L., Hanze,J., Stahl,U., Grimminger,F.,
Kummer,W. and Bohle,R.M. (1998) Real-time quantitative RT±PCR
after laser-assisted cell picking. Nat. Med., 4, 1329±1333.
30. Cuppen,E., Gerrits,H., Pepers,B., Wieringa,B. and Hendriks,W. (1998)
PDZ motifs in PTP-BL and RIL bind to internal protein segments in the
LIM domain protein RIL. Mol. Biol. Cell, 9, 671±683.
31. Carr,C.S. and Sharp,P.A. (1990) A helix±loop±helix protein related to the
immunoglobulin E box-binding proteins. Mol. Cell. Biol., 10,
4384±4388.
32. Phelps,D.E., Hsiao,K.M., Li,Y., Hu,N., Franklin,D.S., Westphal,E.,
Lee,E.Y. and Xiong,Y. (1998) Coupled transcriptional and translational
control of cyclin-dependent kinase inhibitor p18INK4c expression during
myogenesis. Mol. Cell. Biol., 18, 2334±2343.
33. Wang,Y., Newton,D.C., Robb,G.B., Kau,C.L., Miller,T.L., Cheung,A.H.,
Hall,A.V., Van Damme,S., Wilcox,J.N. and Marsden,P.A. (1999) RNA
diversity has profound effects on the translation of neuronal nitric oxide
synthase. Proc. Natl Acad. Sci. USA, 96, 12150±12155.
34. Chung,M.C., Kim,H.K. and Kawamoto,S. (2001) TFEC can function as a
transcriptional activator of the nonmuscle myosin II heavy chain-A gene
in transfected cells. Biochemistry, 40, 8887±8897.
35. Artandi,S.E., Merrell,K., Avitahl,N., Wong,K.K. and Calame,K. (1995)
TFE3 contains two activation domains, one acidic and the other proline-
rich, that synergistically activate transcription. Nucleic Acids Res., 23,
3865±3871.
36. Wu,M., Hemesath,T.J., Takemoto,C.M., Horstmann,M.A., Wells,A.G.,
Price,E.R., Fisher,D.Z. and Fisher,D.E. (2000) c-Kit triggers dual
phosphorylations, which couple activation and degradation of the
essential melanocyte factor Mi. Genes Dev., 14, 301±312.
37. Antequera,F. (2003) Structure, function and evolution of CpG island
promoters. Cell Mol. Life Sci., 60, 1647±1658.
38. Roman,C., Cohn,L. and Calame,K. (1991) A dominant negative form of
transcription activator mTFE3 created by differential splicing. Science,
254, 94±97.
39. Hemesath,T.J., Price,E.R., Takemoto,C., Badalian,T. and Fisher,D.E.
(1998) MAP kinase links the transcription factor Microphthalmia to c-Kit
signalling in melanocytes. Nature, 391, 298±301.
40. Benezra,R., Davis,R.L., Lockshon,D., Turner,D.L. and Weintraub,H.
(1990) The protein Id: a negative regulator of helix±loop±helix DNA
binding proteins. Cell, 61, 49±59.
41. Norton,J.D., Deed,R.W., Craggs,G. and Sablitzky,F. (1998) Id helix±
loop±helix proteins in cell growth and differentiation. Trends Cell Biol.,
8, 58±65.
42. Pozniak,C.D., Radinovic,S., Yang,A., McKeon,F., Kaplan,D.R. and
Miller,F.D. (2000) An anti-apoptotic role for the p53 family member,
p73, during developmental neuron death. Science, 289, 304±306.
43. Yang,A., Kaghad,M., Wang,Y., Gillett,E., Fleming,M.D., Dotsch,V.,
Andrews,N.C., Caput,D. and McKeon,F. (1998) p63, a p53 homolog at
3q27±29, encodes multiple products with transactivating, death-inducing,
and dominant-negative activities. Mol. Cell, 2, 305±316.
44. Nakagawa,T., Takahashi,M., Ozaki,T., Watanabe,K.K., Todo,S.,
Mizuguchi,H., Hayakawa,T. and Nakagawara,A. (2002) Autoinhibitory
regulation of p73 by Delta Np73 to modulate cell survival and death
through a p73-speci®c target element within the Delta Np73 promoter.
Mol. Cell. Biol., 22, 2575±2585.
45. Fillippovich,I., Sorokina,N., Gatei,M., Haupt,Y., Hobson,K.,
Moallem,E., Spring,K., Mould,M., McGuckin,M.A., Lavin,M.F. et al.
(2001) Transactivation-de®cient p73alpha (p73Deltaexon2) inhibits
apoptosis and competes with p53. Oncogene, 20, 514±522.
46. Yang,A., Schweitzer,R., Sun,D., Kaghad,M., Walker,N., Bronson,R.T.,
Tabin,C., Sharpe,A., Caput,D., Crum,C. et al. (1999) p63 is essential for
regenerative proliferation in limb, craniofacial and epithelial
development. Nature, 398, 714±718.
2322 Nucleic Acids Research, 2004, Vol. 32, No. 8
 at K
atholieke U
niversiteit on July 13, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
